Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose The aim of this study was to evaluate whether hepatic arterial infusion concurrent chemora- diotherapy (CCRT) could improve overall survival (OS) in patients with locally advanced hepatocellular carcinoma (LAHCC). Materials and Methods Two databases were reviewed from Yonsei Cancer Center (YCC) and Korean Liver Cancer Study Group (KLCSG) nationwide multi-center hepatocellular carcinoma (HCC) cohort. The CCRT group included 106 patients, with stage III-IV, Child-Pugh classification A, Eastern Cooperative Oncology Group performance status 0 or 1, who underwent definitive CCRT as the initial treatment at YCC. We used propensity score matching to adjust for seven clinical factors, including age, tumor size, TNM stage by the Liver Cancer Study Group of Japan, T stage, Barcelona Clinic Liver Cancer (BCLC) staging system, etiology of HCC, and portal vein invasion, which all differed significantly in the two databases. From the KLCSG cohort enrolled at 32 institutions, 106 patients for the non-CCRT group were defined. Results After propensity score matching, all patient characteristics were balanced between the two groups. The CCRT group had better OS (median, 11.4) than the non-CCRT group (6.6 months, p=0.02). In multivariate analyses for all patients, CCRT (hazard ratio [HR], 1.48; 95% confidence interval [CI], 1.11 to 1.97; p=0.007), tumor size (HR, 1.08; 95% CI, 1.04 to 1.12; p < 0.001), and BCLC stage (HR, 0.54; 95% CI, 0.36 to 0.8; p=0.003) were inde- pendent prognostic factors for OS. Conclusion CCRT showed better OS for LAHCC patients. In LAHCC patients with a good performance and normal liver function, CCRT could be a feasible treatment option. All of these findings need to be validated in prospective clinical trials.
Abstract
Purpose The aim of this study was to evaluate whether hepatic arterial infusion concurrent chemora- diotherapy (CCRT) could improve overall survival (OS) in patients with locally advanced hepatocellular carcinoma (LAHCC). Materials and Methods Two databases were reviewed from Yonsei Cancer Center (YCC) and Korean Liver Cancer Study Group (KLCSG) nationwide multi-center hepatocellular carcinoma (HCC) cohort. The CCRT group included 106 patients, with stage III-IV, Child-Pugh classification A, Eastern Cooperative Oncology Group performance status 0 or 1, who underwent definitive CCRT as the initial treatment at YCC. We used propensity score matching to adjust for seven clinical factors, including age, tumor size, TNM stage by the Liver Cancer Study Group of Japan, T stage, Barcelona Clinic Liver Cancer (BCLC) staging system, etiology of HCC, and portal vein invasion, which all differed significantly in the two databases. From the KLCSG cohort enrolled at 32 institutions, 106 patients for the non-CCRT group were defined. Results After propensity score matching, all patient characteristics were balanced between the two groups. The CCRT group had better OS (median, 11.4) than the non-CCRT group (6.6 months, p=0.02). In multivariate analyses for all patients, CCRT (hazard ratio [HR], 1.48; 95% confidence interval [CI], 1.11 to 1.97; p=0.007), tumor size (HR, 1.08; 95% CI, 1.04 to 1.12; p < 0.001), and BCLC stage (HR, 0.54; 95% CI, 0.36 to 0.8; p=0.003) were inde- pendent prognostic factors for OS. Conclusion CCRT showed better OS for LAHCC patients. In LAHCC patients with a good performance and normal liver function, CCRT could be a feasible treatment option. All of these findings need to be validated in prospective clinical trials.
참고문헌 (25)
- Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- Bruix J, "American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- Fleissig A, "Multidisciplinary teams in cancer care : are they effective in the UK?", Lancet Oncol, 7, pp.935~943 (2006)
- Fennell ML, "The organization of multidisciplinary care teams : modeling internal and external influences on cancer care quality", J Natl Cancer Inst Monogr, 2010, pp.72~80 (2010)
- Zaorsky NG, "Multimodality therapy for patients with high-risk prostate cancer : current status and future directions", Semin Oncol, 40, pp.308~321 (2013)
- Hadziahmetovic M, "Recent advancements in multimodality treatment of gliomas", Future Oncol, 7, pp.1169~1183 (2011)
- Stillwagon GB, "194 hepatocellular cancers treated by radiation and chemotherapy combinations : toxicity and response : a Radiation Therapy Oncology Group Study", Int J Radiat Oncol Biol Phys, 17, pp.1223~1229 (1989)
- Mornex F, "Feasibility and efficacy of high-dose three-dimensionalconformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French Phase II RTF-1 trial", Int J Radiat Oncol Biol Phys, 66, pp.1152~1158 (2006)
- Seong J, "A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea", Liver Int, 29, pp.147~152 (2009)
- Yoon HI, "Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma", J Cancer Res Clin Oncol, 140, pp.1595~1605 (2014)
- "NCCN clinical practice guidelines in oncology, hepatobiliary cancers" (2014)[URL]
- Han KH, "Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis", Cancer, 113, pp.995~1003 (2008)
- Park MS, "Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis", Cancer Chemother Pharmacol, 71, pp.165~173 (2013)
- Ben-Josef E, "Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies", J Clin Oncol, 23, pp.8739~8747 (2005)
- "Report of randomized registration for hepatocellular carcinoma in Korea" (2010)[URL]
- von Elm E, "The Strengthening the Reporting of Observational Studies in Epidemiology(STROBE)statement : guidelines for reporting observational studies", Lancet, 370, pp.1453~1457 (2007)
- Liver Cancer Study Group of Japan, "The general rules for the clinical and pathological study of primary liver cancer" (2000), Kanehara Co. Ltd
- Park JW, "Practice guideline for diagnosis and treatment of hepatocellular carcinoma", Korean J Hepatol, 10, pp.88~98 (2004)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
- Yoon SM, "Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes", Int J Radiat Oncol Biol Phys, 82, pp.2004~2011 (2012)
- Yamada K, "Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 57, pp.113~119 (2003)
- Dawson LA, "Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies", J Clin Oncol, 18, pp.2210~2218 (2000)
- Kim KH, "Therapeutic benefit of radiotherapy in huge (>", =10 cm) unresectable hepatocellular carcinoma, 2014, pp.34, 784~794
- Lee HS, "Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy", Ann Surg Oncol, 21, pp.3646~3653 (2014)